|
- Palazestrant - Wikipedia
Palazestrant is an investigational new drug which is being evaluated for the treatment of estrogen receptor-positive (ER+) breast cancer, with a dual mechanism of action as both a complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD)
- Palazestrant, a novel oral Complete Estrogen Receptor . . . - PubMed
Palazestrant is a novel oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) belonging to a new class of ER-targeting agents that completely blocks estrogen-induced transcriptional activity, regardless of ESR1 mutation status
- Pipeline – Olema Oncology
Our lead investigational drug, palazestrant (OP-1250), is a novel oral compound developed to completely antagonize the estrogen receptor (ER) and block the ER-mediated cancer cell growth and proliferation signal
- Discovery of Palazestrant (OP-1250), a Potent and Orally Bioavailable . . .
Here, we describe our discovery of the investigational drug OP-1250 (palazestrant) OP-1250 is a potent complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) that is active in both WT and mutESR1 breast cancer tumors
- PALAZESTRANT « New Drug Approvals
Palazestrant (OP-1250) is an investigational drug being developed for estrogen receptor-positive (ER+) breast cancer It is a small molecule with a dual mechanism of action, acting as both a complete estrogen receptor antagonist and a selective estrogen receptor degrader (SERD)
- Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist . . .
Given the limitations of approved therapies, there is an unmet need in metastatic ER + breast cancer treatment Here we describe palazestrant (OP-1250), a novel orally bioavailable complete ER antagonist and degrader of both wild-type and mutant ER
- Definition of palazestrant - NCI Drug Dictionary - NCI
Palazestrant blocks estrogen-driven transcriptional activity and induces degradation of ERalpha This inhibits the growth and survival of ERalpha-expressing cancer cells
- Dr Meisel on the Mechanism of Action of Palazestrant in ER+, HER2 . . .
Jane L Meisel, MD, FASCO, discusses the mechanism of action of palazestrant in ER+, HER2– advanced metastatic breast cancer
|
|
|